Company intelligence / Profile preview

EPIRUS Biopharmaceuticals, Inc.

Boston, Massachusetts, USAsec.gov ↗

Ownership: Private
Development stage: Commercial

Overview

EPIRUS developed a pipeline of biosimilar monoclonal antibodies targeting blockbuster biologics. Its lead asset BOW015 was an infliximab biosimilar in global Phase III studies. Other programs were at preclinical or early clinical stages. The company reprioritized its pipeline in later years to focus on rare diseases but did not reach commercialization before ceasing operations.

Therapeutic areas: HematologyImmunology
Modalities: monoclonal antibodies (mAbs)biosimilars
Industry: Biotech

Drug pipeline

4 assets

infliximab-epirus

3 more assets in the full pipeline.

Request access →

Partnerships

Multiple partnerships for regulatory/commercialization efforts globally; specifics not detailed in available sources

Beyond the preview

Go deeper on EPIRUS Biopharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPIRUS Biopharmaceuticals, Inc..

Explore the full profile